Travis Steed
Stock Analyst at Barclays
(2.73)
# 1,989
Out of 4,944 analysts
86
Total ratings
43.48%
Success rate
6.34%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDX Becton, Dickinson and Company | Maintains: Overweight | $279 → $261 | $195.96 | +33.19% | 9 | Apr 7, 2025 | |
| PEN Penumbra | Initiates: Buy | $320 | $257.38 | +24.33% | 1 | Mar 14, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $129.40 | +15.92% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $74.38 | +14.28% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $77.68 | +15.86% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $11.94 | +168.12% | 1 | Nov 5, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $24.11 | +86.64% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $480 → $45 | $13.21 | +240.65% | 1 | Oct 13, 2023 | |
| SYK Stryker | Upgrades: Buy | $315 | $378.95 | -16.88% | 5 | Sep 5, 2023 | |
| PODD Insulet | Maintains: Buy | $365 → $295 | $308.68 | -4.43% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $14.76 | +8.40% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $33 | $11.13 | +196.50% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $103.22 | +55.01% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $482.35 | -34.69% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $1.54 | +419.48% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $13.94 | +79.34% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $14.65 | +480.20% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $79.96 | +56.33% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $92.91 | +56.07% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $102.50 | -50.24% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $175 | $55.16 | +217.26% | 4 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $14.12 | +282.44% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $53.79 | -59.10% | 1 | Jul 17, 2017 |
Becton, Dickinson and Company
Apr 7, 2025
Maintains: Overweight
Price Target: $279 → $261
Current: $195.96
Upside: +33.19%
Penumbra
Mar 14, 2025
Initiates: Buy
Price Target: $320
Current: $257.38
Upside: +24.33%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $129.40
Upside: +15.92%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $74.38
Upside: +14.28%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $77.68
Upside: +15.86%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $11.94
Upside: +168.12%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $24.11
Upside: +86.64%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $13.21
Upside: +240.65%
Stryker
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $378.95
Upside: -16.88%
Insulet
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $308.68
Upside: -4.43%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $14.76
Upside: +8.40%
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $11.13
Upside: +196.50%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $103.22
Upside: +55.01%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $482.35
Upside: -34.69%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $1.54
Upside: +419.48%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $13.94
Upside: +79.34%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $14.65
Upside: +480.20%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $79.96
Upside: +56.33%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $92.91
Upside: +56.07%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $102.50
Upside: -50.24%
May 25, 2021
Initiates: Overweight
Price Target: $175
Current: $55.16
Upside: +217.26%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $14.12
Upside: +282.44%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $53.79
Upside: -59.10%